Zoetis Inc.ZTS

時価総額

$540.9億

PER

動物用医薬品・ワクチン・診断の業界最大手。ワクチン、抗生物質、遺伝子検査、デジタル診断を展開。2022年にオーストラリアの動物医薬企業を約2.4億ドルで買収、2024年10月に飼料添加物事業を約3.09億ドルで売却。北米・欧州を中心に直接販売約45カ国、製品は100カ国超で展開。

概要財務

サマリーテーブルに戻る

	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income before allocation to noncontrolling interests	503	587	339	819	862	1,424	1,500	1,636	2,034	2,111	2,340	2,496
Depreciation and amortization expense	209	204	199	240	242	308	412	441	448	465	491	497
Share-based compensation expense	43	32	43	37	44	53	67	59	58	62	60	74
Asset Impairment Charges	15	10	60	5	3	4	7	43	47	53	46	31
Net loss/(gain) on sales of assets	-	-	-	26	-11	42	20	19	-2	-	118	-23
Inventory Write-down	-	-	94	105	54	54	68	105	46	76	115	97
Deferred taxes	23	-49	-85	-55	127	-112	-79	-62	-80	-286	-61	-338
Settlement of derivative contracts	-	-	-	-	-	-	-	-	-	-114	-	-
Non Cash Transfers to Related Party	-	-	3	3	3	3	3	3	3	3	-	-
Other non-cash adjustments	10	3	-10	-19	-10	14	12	-11	2	-13	8	6
Accounts receivable	99	-69	58	-15	50	67	69	-74	155	137	102	61
Inventories	104	16	262	101	-19	-61	104	346	366	486	361	40
Other assets	24	2	9	50	16	42	51	68	7	-35	95	-52
Accounts payable	-82	-210	17	-28	-10	37	-10	147	-17	-29	13	31
Other liabilities	196	11	70	-295	-57	56	91	91	227	-180	67	114
Other tax accounts, net	9	-9	34	20	85	67	-8	17	-25	98	-34	-17
Net cash provided by operating activities	681	626	664	713	1,346	1,790	1,795	2,126	2,213	1,912	2,353	2,953
Capital expenditures	184	180	224	216	224	338	460	453	477	586	732	655
Acquisitions, net of cash acquired	-	-	654	-	-	114	195	113	14	312	155	8
Purchase of investments	-	-	-	-	-	-	-	-	12	9	4	5
Net proceeds from sale of assets	9	9	2	90	37	56	21	21	2	1	4	1
Proceeds from derivative instrument activity, net	-	-	-	-	-	-	-	27	-44	-23	-12	-62
Proceeds from sale of businesses, net of cash sold	-	-	-	-	-	-	-	-	-	-	96	293
Other investing activities	-	1	10	-	1	7	8	-	1	-	-2	3
Net cash used in investing activities	-179	-187	-1,115	-214	-270	-2,259	-504	-572	-458	-883	-777	-315
Proceeds from (Repayments of) Short-Term Debt	16	-8	-2	-5	-	8	-9	4	-4	2	1	-3
Principal payments on long-term debt	-	-	-	400	750	-	-	500	600	-	1,350	-
Proceeds from Issuance of Senior Long-Term Debt	2,625	-	1,236	-	1,231	1,485	-	1,240	-	1,348	-	-
Payment of debt issuance costs	-	-	-	3	-	-	-	12	-	10	-	-
Payment of consideration related to previous acquisitions	-	-	-	-	-	-	-	2	6	1	3	5
Share-based compensation-related proceeds, net of taxes paid on withholding shares	-	-	-	-	-	-	-	-	-	-38	27	-8
Purchases of treasury stock	-	-	203	300	500	698	626	250	743	1,594	1,092	1,858
Cash dividends paid	98	146	168	188	206	243	314	380	474	611	692	786
Net cash used in financing activities	-200	-154	755	-903	-251	533	-951	123	-1,862	-904	-3,109	-2,660
Effect of exchange-rate changes on cash and cash equivalents	-	-	-	-	-	-	-	-7	-12	-29	-7	-32
Net (decrease)/increase in cash and cash equivalents	-	-	-	-	-	-	-	1,670	-119	96	-1,540	-54
Income taxes	134	278	224	408	455	336	418	418	548	638	754	892
Interest, net of capitalized interest	60	118	117	165	167	190	247	257	253	242	295	274
Capital expenditures	-	9	11	8	5	7	7	3	6	3	2	3
Excise tax accrued on net share repurchases, not paid	-	-	-	-	-	-	-	-	-	-	10	17